WEP Clinical Revenue and Competitors
Estimated Revenue & Valuation
- WEP Clinical's estimated annual revenue is currently $36.8M per year.
- WEP Clinical's estimated revenue per employee is $201,000
Employee Data
- WEP Clinical has 183 Employees.
- WEP Clinical grew their employee count by 33% last year.
WEP Clinical's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Operating Officer | Reveal Email/Phone |
2 | VP and Global Head, Data and Safety Services | Reveal Email/Phone |
3 | VP, Business Development, Expanded Access Programs | Reveal Email/Phone |
4 | VP, Head Regulatory Affairs | Reveal Email/Phone |
5 | Controller at WEP Clinical | Reveal Email/Phone |
6 | VP Strategic Alliances | Reveal Email/Phone |
7 | VP, Project Management | Reveal Email/Phone |
8 | Associate Director, Quality Assurance | Reveal Email/Phone |
9 | Associate Director, QA, RP & RPi | Reveal Email/Phone |
10 | Director Project Management | Reveal Email/Phone |
WEP Clinical Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.8M | 29 | 4% | N/A | N/A |
#2 | $3.2M | 16 | 0% | N/A | N/A |
#3 | $83.2M | 414 | 7% | N/A | N/A |
#4 | $31M | 154 | 56% | N/A | N/A |
#5 | $66.6M | 265 | 0% | $35M | N/A |
#6 | $10.9M | 54 | 6% | N/A | N/A |
#7 | $6.8M | 34 | -6% | N/A | N/A |
#8 | $165.7M | 216 | 14% | $250.7M | N/A |
#9 | $26.5M | 132 | -11% | $637.8K | N/A |
#10 | $49.4M | 246 | 6% | N/A | N/A |
What Is WEP Clinical?
We are a rapidly growing niche pharmaceutical services company operating in four key sectors:- Managed Access Programs (MAP) Unlicensed Medicines Access Clinical Trial Sourcing Reference Product Supply. Our goal is to provide positive measurable outcomes to patients and sponsors but above all else we want to be known as your trusted partner and an extension of your team. UK headquarters established in London in 2008. US Headquarters established in Research Triangle Park, North Carolina in 2012. Our team has many years of pharmaceutical, clinical and regulatory experience gained in companies such as Pfizer, AZ, MSD, GSK, UDG Healthcare, Waymade, Sanofi, Quintiles & Walgreens Boots Alliance. Our facilities have been inspected & licensed by the MHRA, UK Home Office, FDA and all necessary local approval bodies. We are also approved to handle and distribute controlled substances. We are compliant with all relevant GMDP regulations and operate to a high standard of medicines supply. We operate under a comprehensive Quality Management System with robust and compliant standard operating procedures (SOPs) and policies. Our customers and partners include Pharma, Biotechs, Generic and Biosimilar Developers, CROs and Healthcare and Hospital authorities. We are fully committed to a culture of continual development and strive to service our partners needs beyond their expectations We would be happy to answer any questions that you may have regarding WEP Clinical and our products and services.
keywords:N/AN/A
Total Funding
183
Number of Employees
$36.8M
Revenue (est)
33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
WEP Clinical News
Our partners WEP Clinical in the UK have all licenses in place to distribute and supply under the UK Named Patient Program (NPP,) which in...
Prior to joining WEP, Karl worked with organisations including Novartis, Alcon, and most recently Worldwide Clinical Trials, where he was...
"In the initial clinical experience treating Atrial Fibrillation, the system shows ... Characterization" by Ayelet Shapira-Daniels, MD (S-WEP-03)
TapImmune provided a business and clinical update, wherein it said it plans to advance a Phase 2 Company-sponsored clinical trial in ...
... the RCOG to develop clinical guidance that all professionals will be ... campaigning for the change is the Women's Equality Party (WEP).
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $30.1M | 189 | 15% | N/A |
#2 | $38.5M | 212 | 8% | N/A |
#3 | $42.8M | 213 | 29% | N/A |
#4 | $48.2M | 217 | 1% | N/A |
#5 | $60.7M | 220 | -4% | N/A |